Non-Alcoholic Steatohepatitis (NASH)

Our experts partner with sponsors, investigators, patients, and other collaborators to deliver strategic, data-driven solutions for NASH and hepatology studies.

Our clinical trial experience includes over 63 NASH studies, including 12 phase III NASH trials. In addition, we have supported clinical research in a range of indications, including:

• Cholestasis
• Cirrhosis
• Fatty liver disease
• Hepatic encephalopathy
• Hepatobiliary disease or hepatic impairment, (non-specified)
• Liver disease (other)
• Liver impairment / failure
• Liver transplant
• Non-alcoholic steatohepatitis (NASH)
• Primary biliary cholangitis (PBC)
• Primary sclerosing cholangitis (PSC)
• Veno-occlusive disease

Our team is built of MDs, statisticians, regulatory scientists, DPDs, PMs, CTMs, and CRAs with hepatology-specific expertise who understand these complex patient populations and study protocols.

This experience, combined with our data capabilities and global infrastructure, provides clients with greater access to patients, advanced imaging support and overall advancement of hepatology research. 

Patient-centric approach

We are motivated in our daily work by the patients these treatments help, and we work to make clinical trial participation as convenient as possible for patients worldwide. We’ve crafted a superior patient journey, increasing access for potential participants, reducing the burden of participation, and enabling a truly patient-first experience throughout the entire development journey. Our protocols consider a patient’s daily life and standard of care and are free from unnecessary burdens and nuances. Building patient-focused studies not only helps patients who are enrolled but ultimately leads to faster approvals and widespread availability for all hepatology patients.